Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jake Perkins

Physician Assistant San Diego, CA Physician Assistant

NPI 1386288686 CMS profile 10536098

5321 Aberdeen St, San Diego, CA 92117

Open in the dashboard

General payments

$18,456

1,021 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jake Perkins of San Diego, CA is reported in the CMS Open Payments database as having received $18,456 across 1,021 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,486 179
2024 General $3,686 188
2023 General $3,034 179
2022 General $4,066 239
2021 General $4,185 236

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jake Perkins
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jake Perkins were reported at $3,486. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jake Perkins Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $4,185 $132 $37–$438 $132
2022 $4,066 $155 $48–$522 $149
2023 $3,034 $167 $52–$557 $160
2024 $3,686 $178 $55–$600 $164
2025 $3,486 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,170 250 payments
  2. UCB, Inc. $1,747 85 payments
  3. Teva Pharmaceuticals USA, Inc. $901 57 payments
  4. Lundbeck LLC $827 33 payments
  5. Novartis Pharmaceuticals Corporation $748 59 payments
  6. Biogen, Inc. $730 34 payments
  7. Biohaven Pharmaceuticals, Inc. $724 21 payments
  8. Amgen Inc. $713 48 payments
  9. Neurocrine Biosciences, Inc. $549 21 payments
  10. Pfizer Inc. $540 38 payments
  11. Other $7,806 375 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $18,198 1,015 payments
  2. Education $258 6 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $2,336 183 payments
  2. QULIPTA $1,311 111 payments
  3. NURTEC ODT Primary Care $1,074 46 payments
  4. Zilbrysq $823 38 payments
  5. AIMOVIG $654 46 payments
  6. VYEPTI $617 23 payments
  7. Briviact $539 27 payments
  8. INGREZZA $496 19 payments
  9. UPLIZNA $495 14 payments
  10. NURTEC ODT Pain $460 35 payments
  11. Other $10,919 590 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,354

Median for Physician Assistant: 241

Drug cost

$119,472

Median for Physician Assistant: $4,110

Branded share of claims

17.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Emgality Pen Galcanezumab-Gnlm Brand 54 $40,634
Aimovig Autoinjector Erenumab-Aooe Brand 19 $17,481
Ajovy Autoinjector Fremanezumab-Vfrm Brand 15 $17,103
Nurtec Odt Rimegepant Sulfate Brand 13 $15,191
Ajovy Syringe Fremanezumab-Vfrm Brand 13 $9,536
Memantine Hcl Generic 156 $4,669
Gabapentin Generic 277 $2,187
Pregabalin Generic 103 $1,673
Carbidopa-Levodopa Carbidopa/Levodopa Brand 58 $1,559
Donepezil Hcl Generic 84 $953

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilbrysq
$385 — —
UBRELVY
$373 — —
QULIPTA
$243 — —
Briviact
$223 — —
VYEPTI
$222 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

1,021 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record